Betamethasone

# Betamethasone ## Overview - **Classification**: Corticosteroid, Glucocorticoid - **Mechanism**: Binds to intracellular glucocorticoid receptors, modulating gene expression to inhibit inflammatory mediators and suppress immune responses. ## Primary Indications 1. **Anti-inflammatory/Immunosuppression**: Management of various steroid-responsive conditions (e.g., asthma, severe allergies, dermatoses, rheumatic disorders). 2. **Antenatal Lung Maturation**: Prevention of respiratory distress syndrome (RDS) in premature infants. 3. **Topical Dermatoses**: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ## Adult Dosing ### Systemic (IM/PO) **Antenatal Lung Maturation (Betamethasone phosphate + acetate)** - **Dose**: **12 mg** - **Frequency**: Every 24 hours (2 doses total) - **Route**: Intramuscular (IM) - **Duration**: Two doses given 24 hours apart. - **Special Considerations**: Administer to pregnant women at risk of preterm delivery between **24 and 34 weeks gestation**. **Anti-inflammatory/Immunosuppressive (Betamethasone oral/IM)** - **Dose**: **0.5-9 mg** - **Frequency**: Once daily or in divided doses - **Route**: Oral (PO) or Intramuscular (IM) - **Duration**: Highly variable, dependent on condition and patient response. ### Topical **Corticosteroid-Responsive Dermatoses (e.g., Betamethasone dipropionate 0.05% cream)** - **Dose**: Apply a thin film to affected areas - **Frequency**: Once or twice daily - **Route**: Topically - **Duration**: Up to **2 weeks**. Re-evaluate if no improvement. - **Maximum Dose**: Do not exceed **50 g/week** or treat > 20% Body Surface Area for prolonged periods. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment guidelines. Use with caution due to potential fluid retention. - **Hepatic Impairment**: No specific dose adjustment guidelines, but metabolism may be altered. Monitor for increased effects. - **Elderly Patients**: Increased risk of adverse effects (e.g., osteoporosis, skin thinning, hyperglycemia). Use lowest effective dose for shortest duration. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **0.0175-0.25 mg/kg/day** - **Frequency**: In 1-4 divided doses - **Route**: Oral (PO) or Intramuscular (IM) - **Maximum**: Highly individualized; monitor closely for growth suppression. - **Special Notes**: Systemic use is generally avoided unless absolutely critical due to growth and HPA axis suppression risk. Topical high-potency betamethasone is contraindicated. ### Infants (1-12 months) - **Dose**: **0.0175-0.25 mg/kg/day** - **Frequency**: In 1-4 divided doses - **Route**: Oral (PO) or Intramuscular (IM) - **Maximum**: Highly individualized. - **Special Notes**: Systemic use requires careful monitoring for growth and HPA axis suppression. High-potency topical betamethasone is not recommended. ### Children (1-12 years) - **Dose**: **0.0175-0.25 mg/kg/day** - **Frequency**: In 1-4 divided doses - **Route**: Oral (PO) or Intramuscular (IM) - **Maximum**: **12 mg/day** (or adult equivalent based on indication). - **Special Notes**: For topical use, generally prefer lower potency steroids. If high-potency betamethasone is necessary, limit to small areas (<10% BSA) and short durations (<2 weeks). ### Adolescents (13-18 years) - **Dose**: Follow adult dosing guidelines. - **Frequency**: As per adult regimen. - **Route**: Oral (PO), Intramuscular (IM), or Topical. - **Maximum**: **12 mg/day** (systemic) or **50 g/week** (topical). ## Safety Information ### Contraindications - **Absolute**: Systemic fungal infections (untreated). - **Absolute**: Live or live attenuated vaccines (during immunosuppressive doses). - **Absolute**: Known hypersensitivity to betamethasone or any component. - **Relative**: Untreated serious infections, ocular herpes simplex, active tuberculosis (untreated). ### Common Adverse Effects - **Very Common (>10%)**: Fluid retention, hyperglycemia, increased appetite, mood changes, insomnia. - **Common (1-10%)**: HPA axis suppression (with prolonged use), osteoporosis, muscle weakness, skin thinning/striae (topical), cataracts, glaucoma, weight gain. - **Serious but Rare**: Adrenal crisis (upon abrupt withdrawal), GI perforation, aseptic necrosis, acute pancreatitis, severe hypersensitivity reactions, Cushing's syndrome (prolonged high dose). ### Key Drug Interactions - **CYP3A4 Inducers (e.g., Rifampin, Phenytoin)**: Decrease betamethasone effects; monitor for reduced efficacy. - **CYP3A4 Inhibitors (e.g., Ketoconazole, Macrolides)**: Increase betamethasone effects; monitor for toxicity. - **NSAIDs**: Increased risk of GI ulceration/bleeding; use with caution. - **Warfarin**: May alter anticoagulant effect; monitor INR closely. - **Diuretics (Thiazide/Loop)**: Increased risk of hypokalemia. ## Monitoring & Follow-up - **Before Treatment**: Blood pressure, weight, electrolytes, glucose, bone mineral density (for long-term systemic use), eye exam (for long-term systemic use). - **During Treatment**: Blood pressure, weight, serum electrolytes, blood glucose, signs of infection, HPA axis suppression (upon withdrawal), bone density (for chronic use). Monitor growth velocity in children. - **Clinical Signs**: Edema, mood changes, sleep disturbances, signs of infection, GI distress, muscle weakness, visual changes. ## Clinical Pearls - 💡 **Tip 1**: Administer systemic corticosteroids in the morning to mimic natural cortisol rhythm and reduce insomnia. - 💡 **Tip 2**: Taper systemic betamethasone gradually after prolonged therapy to prevent adrenal insufficiency. - 💡 **Tip 3**: For topical use, apply a thin layer to clean, dry skin. Do not apply to face, groin, or axillae unless specifically directed. - 💡 **Tip 4**: Antenatal betamethasone is most effective when administered **24 hours prior to delivery**, but any dose is better than none if delivery is imminent. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.